Resource Summary Report

Generated by RRID on Sep 9, 2026

Recombinant Anti-Macrophage Inflammatory Protein 1 alpha / CCL3 + CCL3L1 antibody [EPR23751-54]

RRID:AB_3094596
Type: Antibody

Proper Citation

Abcam Cat# ab259372, RRID:AB_3094596

Antibody Information

URL: http://antibodyregistry.org/AB_3094596

Proper Citation: Abcam Cat# ab259372, RRID:AB_3094596

Target Antigen: Macrophage Inflammatory Protein 1 alpha / CCL3 + CCL3L1

Host Organism: Rabbit

Clonality: recombinant monoclonal

Comments: Applications: Flow Cyt (Intra), WB, IHC-P, IP, ICC/IF

Antibody Name: Recombinant Anti-Macrophage Inflammatory Protein 1 alpha / CCL3 + CCL3L1 antibody [EPR23751-54]

Description: This recombinant monoclonal targets Macrophage Inflammatory Protein 1 alpha / CCL3 + CCL3L1

Target Organism: mouse, human

Clone ID: EPR23751-54

Antibody ID: AB_3094596

Vendor: Abcam

Catalog Number: ab259372

Record Creation Time: 20240227T034902+0000

Record Last Update: 20260829T122752+0000

Ratings and Alerts

No rating or validation information has been found for Recombinant Anti-Macrophage Inflammatory Protein 1 alpha / CCL3 + CCL3L1 antibody [EPR23751-54].

No alerts have been found for Recombinant Anti-Macrophage Inflammatory Protein 1 alpha / CCL3 + CCL3L1 antibody [EPR23751-54].

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Chen F, et al. (2026) CCL3+ Neutrophil Signature Predicts Response to Neoadjuvant Toripalimab plus Chemotherapy in Patients with Hypopharyngeal Squamous Cell Carcinoma: A Phase II Trial. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(11), 2166.

Xu W, et al. (2025) NFE2-driven neutrophil polarization promotes pancreatic cancer liver metastasis progression. Cell reports, 44(2), 115226.

Tatekoshi Y, et al. (2025) Protein O-GlcNAcylation and hexokinase mitochondrial dissociation drive heart failure with preserved ejection fraction. Cell metabolism, 37(7), 1584.

Xiao Y, et al. (2025) HEBP2-governed glutamine competition between tumor and macrophages dictates immunotherapy efficacy in triple-negative breast cancer. Cell metabolism.